AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17270614
Drug: Urethral botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral botulinum A toxin (BoNT‐A) injection
Trial: 15520109
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) and supplemental iron therapy
Trial: 28218006
Drug: Red laser
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red laser (660 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Trial: 28218006
Drug: Infrared laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared laser (790 nm) treatment with 4 j/cm² in TMJs and 8 j/cm² in muscles, applied in three sessions.
Trial: 25708022
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg droxidopa
Trial: 25708022
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg droxidopa
Trial: 10081530
Drug: Continuous interscalene
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous interscalene brachial plexus block with bupivacaine (1.25 mg kg‐1 + 0.25 mg kg‐1 h‐1)
Trial: 10081530
Drug: Morphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5 mg i.m. and 2 mg i.v.)
Trial: 10081530
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with morphine (bolus 1 mg)
Trial: 7553233
Drug: Topical interferon-beta
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon-beta cream
Trial: 2187327
Drug: Enteric-coated sodium
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated sodium fluoride tablets and calcium supplements
Trial: 2187327
Drug: Enteric-coated sodium
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated sodium fluoride tablets and calcium supplements with vitamin D
Trial: 41455
Drug: Choline chloride
RxNorm normalized name: Choline Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline chloride (up to 20 g/day)
Trial: 31811360
Drug: Twice-daily oral
RxNorm normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily oral iron therapy (60 mg elemental iron twice daily)
Trial: 31811360
Drug: Alternate-day oral
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day oral iron therapy (120 mg iron on alternate days)
Trial: 26132140
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (50 mg/day)
Trial: 22004765
Drug: Tanezumab 200
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 200 μg/kg
Trial: 16542198
Drug: Saquinavir soft-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir soft-gel capsules 1200 mg three times daily for 3 days
Trial: 15307694
Drug: Compound Fructus
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Fructus Arctii Mixture (FAM)
Trial: 11124359
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg 9-methylene PGE(2) vaginal gel (meteneprost)
Trial: 11124359
Drug: 600 microg
RxNorm normalized name: Fentanyl 600 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 microg oral PGE(1) (misoprostol)
Trial: 11124359
Drug: Oral PGE(1)
RxNorm normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral PGE(1) (misoprostol)
Trial: 11124359
Drug: 9-methylene vaginal
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-methylene vaginal PGE(2) gel (meteneprost)
Trial: 9310802
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration (SQA) of inhaled nitric oxide (NO) at 1, 3, and 6 ppm
Trial: 9310802
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration (CTA) of inhaled nitric oxide (NO) at 1, 3, and 6 ppm
Trial: 8379713
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of autologous platelet-rich plasma (PRP)
Trial: 8379713
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of autologous whole blood harvested immediately before cardiopulmonary bypass
Trial: 2876576
Drug: ICI-118.551 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI-118.551 (50 mg X 3)
Trial: 2876576
Drug: dl-propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-propranolol (80 mg X 3)
Trial: 30460369
Drug: Narrowband ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband ultraviolet B phototherapy and topical corticosteroid
Trial: 30460369
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid only
Trial: 29158663
Drug: DA‐2802 (319
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA‐2802 (319 mg)
Trial: 29158663
Drug: TDF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF (300 mg)
Trial: 19406293
Drug: Additional ward
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional ward treatment
Trial: 16500346
Drug: Fallopian tube
RxNorm normalized name: SUS SCROFA FALLOPIAN TUBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fallopian tube sperm perfusion (FSP) with 4 mL of inseminate
Trial: 16500346
Drug: Intrauterine tuboperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine tuboperitoneal insemination (IUTPI) with 10 mL of inseminate
Trial: 15625998
Drug: Cincinnati Prehospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cincinnati Prehospital Stroke Scale (CPSS) administered by laypersons over the telephone
Trial: 11583725
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg fluvastatin twice daily
Trial: 8040674
Drug: Ifosfamide (IFOS)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IFOS) 2 g/m2/d for 4 days IV plus mesna
Trial: 8040674
Drug: Carboplatin (CARB)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CARB) 560 mg/m2 IV over 1 hour
Trial: 8040674
Drug: Iproplatin (CHIP)
RxNorm normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iproplatin (CHIP) 325 mg/m2 IV over 2 hours
Trial: 8040674
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPIR) 90 mg/m2 IV push
Trial: 8040674
Drug: CECA (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CECA (cisplatin 90 mg/m2 IV on day 1, etoposide 200 mg/m2 IV on day 3, cyclophosphamide 150 mg/m2/d orally on days 7 to 13, doxorubicin 35 mg/m2 IV on day 14)
Trial: 8040674
Drug: HDP/VP/CA (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDP/VP/CA (cisplatin 40 mg/m2 IV on days 1 to 5 and etoposide 200 mg/m2 IV on days 2 to 4 alternating with cyclophosphamide 150 mg/m2/d orally on days 1 to 7 and doxorubicin 35 mg/m2 IV on day 8)
Trial: 25989985
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection with physiotherapy
Trial: 25989985
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection with physiotherapy
Trial: 19234844
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg famotidine in 10 ml saline
Trial: 10021958
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml saline
Trial: 10770452
Drug: Sertraline 150
RxNorm normalized name: sertraline 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 150 mg/day
Trial: 10770452
Drug: Alprazolam 1
RxNorm normalized name: alprazolam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1 mg orally
Trial: 6832203
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg administered preoperatively
Trial: 6832203
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg administered postoperatively
Trial: 31407353
Drug: Melatonin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (1 mg per day for 1 month)
Trial: 31407353
Drug: Placebo (NSPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NSPT and placebo capsules for 1 month)
Trial: 24964358
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitors (PI/r)
Trial: 23591103
Drug: Onabotulinumtoxin-A injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Onabotulinumtoxin-A injections
Trial: 6369348
Drug: Combined medication
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medication of 150 mg Chlorimipramine and 9 mg p.d. Haloperidol (given over six days)
Trial: 2959232
Drug: Ramipril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (10 mg p.o.)
Trial: 23237817
Drug: Modified tumescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified tumescent solution
Trial: 20544159
Drug: Functional splint
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional splint used during activities of daily living for 180 days
Trial: 20544159
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group used the splint only during evaluations for the first 90 days and during activities of daily living for the following 90 days
Trial: 8899256
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg depot‐medroxyprogesterone acetate (DMPA), intramuscularly on days 42 + 1 and 126 + 1 postpartum
Trial: 6418690
Drug: 1% sodium
RxNorm normalized name: Dextrose 5% and 0.11% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% sodium cromoglycate (SC) solution t.i.d. by means of a home nebulizer
Trial: 6418690
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml placebo (water) nebulization
Trial: 9455696
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (30 mg per day for 1 month)
Trial: 3280304
Drug: Increasing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing the dose until the level reached and stayed at the therapeutic range (study arm B)
Trial: 31115626
Drug: Composite criteria
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite criteria using tumor size < 6.0 cm, tumor number < 8, alpha-fetoprotein < 465 ng/mL, TBRmax < 2.8
Trial: 19440013
Drug: Eutectic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eutectic mixture of local anesthetics cream (EMLA)
Trial: 17848798
Drug: Phantasy Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phantasy Therapy
Trial: 9010894
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of one active treatment and placebo
Trial: 23982855
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg lidocaine and 100 % O(2) (group L)
Trial: 23982855
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg lidocaine and a mixture of 67 % N(2)O/O(2) (group LN)
Trial: 21761394
Drug: Caffeine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150 mg) + Taurine (2 g)
Trial: 14747687
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g of fruits and vegetables
Trial: 14578137
Drug: 600 g
RxNorm normalized name: PETROLATUM 600 g in 1000 g TOPICAL OINTMENT [EltaMD Laser Balm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 g of fruits and vegetables
Trial: 8529054
Drug: levodopa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa (200 mg) + benserazide (50 mg)
Trial: 27120292
Drug: (-)-OSU6162 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-OSU6162 at a dose of 15 mg twice a day
Trial: 22035984
Drug: MPS silane
RxNorm normalized name: silane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPS silane (ESPE‐Sil, 3M ESPE) applied to all specimens, left to react at 20°C for 2 min, followed by heat treatment at 38°C, 79°C, or 100°C for 1 min.
Trial: 22035984
Drug: Heat treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatments (G38, G79, G100).
Trial: 22035984
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (GC) received no silane treatment.
Trial: 12032036
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL with epinephrine 2 microg/mL
Trial: 12032036
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL without epinephrine
Trial: 8834415
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg haloperidol
Trial: 1650128
Drug: tetravalent rhesus
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetravalent rhesus rotavirus vaccine with small-volume (2.5-mL) antacid buffer
Trial: 1650128
Drug: tetravalent rhesus
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetravalent rhesus rotavirus vaccine with large-volume (30-mL) antacid buffer
Trial: 1650128
Drug: tetravalent rhesus
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetravalent rhesus rotavirus vaccine alone
Trial: 1650128
Drug: tetravalent rhesus
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tetravalent rhesus rotavirus vaccine with oral polio vaccine
Trial: 1650128
Drug: oral polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral polio vaccine serotype 1
Trial: 1650128
Drug: oral polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral polio vaccine serotype 2
Trial: 1650128
Drug: oral polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral polio vaccine serotype 3
Trial: 30859967
Drug: Valbenazine (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine (open-label treatment)
Trial: 27823710
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) 1000 mg as a single infusion
Trial: 27823710
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) 1000 mg
Trial: 25024410
Drug: Intracoronary (IC)
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary (IC) salbutamol provocation at a dosage of 0.30 µg/min for 5 minutes
Trial: 23062392
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 300 μg once daily
Trial: 23062392
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 400 μg once daily
Trial: 23062392
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 250 μg twice daily (active control)
Trial: 15381545
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% tacrolimus ointment plus 308-nm excimer laser therapy (group A)
Trial: 15381545
Drug: 308-nm excimer
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 308-nm excimer laser monotherapy (group B)
Trial: 11194214
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks)
Trial: 9100602
Drug: hCRH (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCRH (1 microgram/kg) stimulation with 5% NaCl (0.06 mL.kg/min for 120 min)
Trial: 9100602
Drug: Isotonic volume
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic volume loading (0.9% NaCl, 12 mL.kg.60 min)
Trial: 944395
Drug: Flufenamic acid
RxNorm normalized name: Flufenamic acid
DrugBank: Flufenamic acid (DB02266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flufenamic acid (125 mg four to six times per attack)
Trial: 944395
Drug: Common antimigraine
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common antimigraine drugs
Trial: 20854770
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antidepressant medication and cognitive-behavioral therapy focused on suicide prevention (Comb)
Trial: 20854770
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy focused on suicide prevention
Trial: 3462459
Drug: Certain therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certain therapies
Trial: 29678987
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (Octafibrin/Fibryga; Octapharma) - 4g administered within 24 hours of cardiopulmonary bypass
Trial: 29678987
Drug: Cryoprecipitate -
RxNorm normalized name: Cryoprecipitate - CMV negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoprecipitate - 10 units (dose-equivalent to 4g) administered within 24 hours of cardiopulmonary bypass
Trial: 26648582
Drug: Ascorbic acid-loaded
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid-loaded dissolving microneedle patch
Trial: 25018648
Drug: Desvenlafaxine 200
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 200 mg/day
Trial: 25018648
Drug: Desvenlafaxine 400
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 400 mg/day
Trial: 12403958
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg trafermin
Trial: 12403958
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg trafermin
Trial: 12403958
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg trafermin (post hoc subgroup analysis)
Trial: 7791258
Drug: Alprazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Trial: 7791258
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (300 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Trial: 7791258
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Trial: 29779834
Drug: High-intensity intervention
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity intervention (weekly sessions for 12 months with home-based assessments and advice, n=100)